Timothy Cavanaugh, MD
Ophthalmology · Overland Park, KSNPI 1083686729
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Alcon at 36.2% of the total. Reporting peaked in 2022 at $942 and has fallen 50.8% since, to $464 in 2025.
Across 171 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$458
- Sun Pharmaceutical Industries Inc.$302
- Glaukos Corporation$273
- Bausch & Lomb, A Division Of Bausch Health US, LLC$207
- Bausch & Lomb Americas Inc.$186
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,56199%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 48 | $1,664 |
| AbbVie(2 entities) | 23 | $458 |
| Sun Pharmaceutical Industries Inc. | 14 | $302 |
| Glaukos Corporation | 11 | $273 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $207 |
| Bausch & Lomb Americas Inc. | 9 | $186 |
| Oyster Point Pharma, Inc. | 9 | $175 |
| Dompe US, Inc. | 7 | $168 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $158 |
| Mallinckrodt Hospital Products Inc. | 1 | $145 |
| Avedro Inc. | 1 | $126 |
| Kala Pharmaceuticals, Inc. | 8 | $116 |
| Viiv Healthcare Company | 3 | $82 |
| Rxsight Inc | 4 | $80 |
| Optos, Inc. | 1 | $73 |
| Ocular Therapeutix, Inc. | 4 | $65 |
| Biotissue Holdings Inc. | 2 | $60 |
| Novartis | 3 | $54 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| Beaver-visitec International, Inc. | 1 | $31 |
| Shire North American Group Inc | 1 | $23 |
| Lombart Brothers, Inc. | 1 | $22 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Thea Pharma Inc. | 1 | $18 |
| Alcon Research LLC | 1 | $15 |
| Staar Surgical Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ophthalmic Surgical Adjuncts$375
- ARGOS$292
- Clareon$237
- AcrySof$148
- ACTHAR$145
- Clareon PanOptix Pro$143
- AcrySof IQ VIVITY IOL$135
- RESTASIS$125
How this compares
$4,591 in reported general payments places this provider in the 80th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 38 | $33,077 |
| Loteprednol Etabonate | 206 | $28,195 |
| Prednisolone Acetate | 671 | $25,283 |
| Difluprednate | 95 | $9,543 |
| LumiganBimatoprost | 25 | $8,494 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 218 | $1,906 |
| Fluorometholone | 20 | $1,837 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,659 |
| ValacyclovirValacyclovir Hcl | 41 | $1,629 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 230 | $1,607 |
| Brimonidine Tartrate | 47 | $1,503 |
| Diclofenac Sodium | 120 | $1,063 |
| Timolol Maleate | 72 | $516 |
| Latanoprost | 14 | $341 |
| Dorzolamide Hcl | 15 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $458 | $41,57163 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $207 | $28,195206 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Overland Park
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Jason StahlOverland Park$10K
- Christopher KetchersideOverland Park$6K
- Selena FuOverland Park$5K
- Johann OhlyOverland Park$4K
- Keith WarrenOverland Park$4K
- Austin AndersenOverland Park$3K
- Kristin Schmid BiggerstaffOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.